Chronic pain is not a level playing field — and mounting evidence suggests the gap between how men and women experience, report, and receive care for pain has profound consequences for half the population. This disparity sits at the intersection of biology, clinical bias, and research design, making it one of the more consequential blind spots in modern medicine.
The French national research institute INSERM is drawing attention to the disproportionate burden of chronic pain among women through its participatory research initiative, Dolora. The project explicitly integrates patient voices — specifically women living with chronic pain — into the scientific process itself, a methodology that aims to close the gap between clinical investigation and lived experience. The broader context is stark: conditions such as fibromyalgia, endometriosis, migraine, and rheumatoid arthritis affect women at substantially higher rates, yet women are historically more likely to have their pain minimized, misattributed to psychological causes, or dismissed outright during clinical encounters.
The Dolora initiative reflects a growing recognition within pain research that the field has long been shaped by male-dominant study populations and animal models. Foundational pain neuroscience conducted predominantly in male rodents missed critical sex-based differences in nociceptive signaling — particularly the distinct roles of immune cells like microglia in male versus female pain pathways, a finding that emerged only in the last decade. Clinically, women with chronic conditions wait longer for diagnoses, receive fewer analgesic prescriptions, and are more frequently offered psychotherapy rather than pharmacological treatment compared to male counterparts with equivalent pain scores. Participatory research models, while promising for legitimizing patient-reported outcomes, are still observational and face challenges in scalability. This initiative is best understood as early-stage and directionally important — not yet practice-changing — but it signals a meaningful institutional pivot toward sex-informed pain medicine.